AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.355

-0.005-0.21%

Volume:714.66K

Turnover:1.69M

Market Cap:3.05B

PE:-22.94

High:2.395

Open:2.390

Low:2.330

Close:2.360

52wk High:3.310

52wk Low:1.880

Shares:1.30B

Float Shares:786.49M

Volume Ratio:0.56

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.103

EPS(LYR):-0.118

ROE:-18.22%

ROA:-6.16%

PB:3.81

PE(LYR):-19.96

Loading ...

Overview Company News Filings

Mesoblast Ltd-ASX CEO Connect Presentation

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership

Simply Wall St.

ASX Penny Stocks With Market Caps Under A$3B To Consider

Simply Wall St.

Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L

Simply Wall St.

Is Completing Phase 3 Enrollment For Rexlemestrocel-L Reshaping The Investment Case For Mesoblast (ASX:MSB)?

Simply Wall St.

Mesoblast posts Q3 Ryoncil net revenue of US$30.3 million

Mesoblast Reports Ryoncil® Net Revenues of US$30.3M and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

THOMSON REUTERS

Stock Track | Mesoblast Plummets 5.41% Intraday Following Quarterly Ryoncil Revenue Report

Mesoblast Ltd - Reports Qtrly Ryoncil Net Revenues of $30.3 Mln

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership In April 2026

Simply Wall St.

Mesoblast files Form 3 as director Lynette Cobley reports beneficial ownership

Stock Track | Mesoblast Soars 5.12% Intraday on Patient Recruitment Milestone in Phase 3 Back Pain Trial

BUZZ-ASX-shares of Mesoblast rise after back-treatment drug hits patent target

Mesoblast hits recruitment target in Phase 3 chronic low back pain trial

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

THOMSON REUTERS

Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives

Simply Wall St.

Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil

Simply Wall St.

Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline

Simply Wall St.

Mesoblast Acquires Exclusive License to Chimeric Antigen Receptor Platform; Shares Up 7%

MT Newswires Live

Australian stocks edge higher as investors focus on US-Iran talks

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/MSB.AU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.355,"timestamp":1787537656960,"preClose":2.36,"halted":0,"volume":714656,"delay":0,"changeRate":-0.002118644067796565,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.10265821795880557,"marketStatus":"Trading","change":-0.005,"latestTime":"08-24 12:14:27 AEST","open":2.39,"high":2.395,"low":2.33,"amount":1689193,"amplitude":0.027542,"askPrice":2.36,"askSize":10430,"bidPrice":2.35,"bidSize":32786,"shortable":3,"etf":0,"ttmEps":-0.10265821795880557,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787551200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":2.36,"openAndCloseTimeList":[[1787529600000,1787551200000]],"volumeRatio":0.561815,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.36,"auctionPrice":2.39,"auctionVolume":3958,"auctionTime":1787529540683,"referenceTime":1787308204093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787529540683}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-6.16%","roe":"-18.22%","lyrEps":-0.117982,"volumeRatio":0.561815,"shares":1296862776,"dividePrice":0,"high":2.395,"amplitude":0.027542,"preClose":2.36,"low":2.33,"week52Low":1.88,"pbRate":"3.81","psRate":"33.48","week52High":3.31,"institutionHeld":0,"latestPrice":2.355,"committee":0.517308,"eps":-0.10265821795880557,"divideRate":0,"volume":714656,"delay":0,"ttmEps":-0.10265821795880557,"open":2.39,"prevYearClose":2.72,"prevWeekClose":2.36,"prevMonthClose":2.05,"prevQuarterClose":1.955,"fiveDayClose":2.45,"twentyDayClose":2.14,"sixtyDayClose":2.14,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640996638","title":"Mesoblast Ltd-ASX CEO Connect Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2640996638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640996638?lang=en_us&edition=fundamental","pubTime":"2026-06-02 09:51","pubTimestamp":1780365084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUE13GZMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640898689","title":"ASX Growth Companies With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2640898689","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640898689?lang=en_us&edition=fundamental","pubTime":"2026-06-01 03:08","pubTimestamp":1780254489,"startTime":"0","endTime":"0","summary":"As Australian shares rebound from a significant market downturn, driven by global events and domestic fiscal policies, investors are keenly observing the landscape for opportunities. In this environment, growth companies with high insider ownership can be particularly appealing due to their potential for alignment of interests between management and shareholders.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/asx-growth-companies-with-high-insider-ownership-13","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/asx-growth-companies-with-high-insider-ownership-13","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PNI.AU","VAP.AU","BK7005","BK7016","BK7062","TOR.AU","SPL.AU","BBOZ.AU","AR1.AU","IOZ.AU","BK7023","BK7501","BK7017","BK7096","DACE.AU","GIVE.AU","BK7067","QFN.AU","AEM.AU","QRE.AU","EIQ.AU","STW.AU","EIGA.AU","BK7095","OZF.AU","VAS.AU","XJO.AU","IISV.AU","E200.AU","BK7508","AV1.AU","FRS.AU","BK7162","MAU.AU","OZR.AU","IMLC.AU","MSB.AU","ZYAU.AU","IIGF.AU","XAO.AU","BK7104","BEAR.AU","XKO.AU","GEAR.AU","BK7110","SLF.AU","SKS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638656561","title":"ASX Penny Stocks With Market Caps Under A$3B To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2638656561","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638656561?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:05","pubTimestamp":1779933920,"startTime":"0","endTime":"0","summary":"Australian shares are poised for a slight retreat, influenced by Wall Street's recent cooling and ongoing global economic discussions. Despite the fluctuating market conditions, penny stocks—often overlooked due to their smaller size or newer status—can still present valuable opportunities when backed by solid financials. In this article, we explore several promising Australian penny stocks that combine financial strength with potential for long-term growth.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ami/aurelia-metals-shares/news/asx-penny-stocks-with-market-caps-under-a3b-to-consider","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ami/aurelia-metals-shares/news/asx-penny-stocks-with-market-caps-under-a3b-to-consider","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["OZR.AU","XAO.AU","QRE.AU","BK7067","AMI.AU","BK7506","E200.AU","OZF.AU","IIGF.AU","IOZ.AU","BK7089","BK7508","MSB.AU","IISV.AU","BEAR.AU","VAS.AU","SLF.AU","BBOZ.AU","GDG.AU","VAP.AU","BK7095","QFN.AU","EIGA.AU","XKO.AU","XJO.AU","IMLC.AU","BK7501","GIVE.AU","STW.AU","ZYAU.AU","DACE.AU","GEAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972051","title":"Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972051","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972051?lang=en_us&edition=fundamental","pubTime":"2026-05-07 11:57","pubTimestamp":1778126267,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has reached full patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain, a key step toward confirmatory data supporting a potential US regulatory filing.\nSee our latest analysis for Mesoblast.\nDespite the latest clinical milestone, Mesoblast’s 1 day share price return of a 4.13% decline and 7 day share price return of a 5.86% decline show some cooling momentum. However, the 3 year total shareholder return of 102.23% reflects a strong...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","BK7067","BK7508","MSB.AU","BK7501","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632227266","title":"Is Completing Phase 3 Enrollment For Rexlemestrocel-L Reshaping The Investment Case For Mesoblast (ASX:MSB)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632227266","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632227266?lang=en_us&edition=fundamental","pubTime":"2026-05-02 11:34","pubTimestamp":1777692888,"startTime":"0","endTime":"0","summary":"In late April 2026, Mesoblast Limited reported it had completed patient recruitment for its pivotal 300-patient Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study designed around a 12-month pain reduction endpoint and supported by the therapy’s RMAT designation.\nThis milestone moves rexlemestrocel-L closer to potential FDA submission for a condition affecting over 7 million Americans and heavily tied to opioid use,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-completing-phase-3-enrollment-for-rexlemestrocel-l-reshap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-completing-phase-3-enrollment-for-rexlemestrocel-l-reshap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7508","BK7067","BK4006","MSB.AU","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631601579","title":"Mesoblast posts Q3 Ryoncil net revenue of US$30.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631601579","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631601579?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:55","pubTimestamp":1777510520,"startTime":"0","endTime":"0","summary":"Mesoblast reported fiscal third-quarter net revenue from Ryoncil of US$30.3 million on gross sales of US$35.3 million.Net operating cash spend narrowed to US$4.1 million, supported by receipts of US$34.6 million.Cash on hand totaled US$122 million at March 31, 2026.Patient recruitment target was reached in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain.Exclusive worldwide license was secured for patented CAR technology platform to develop precision-enhanced MSC products.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL6rmgv1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4112","BK7508","BK7067","NDAQ","LU2095319765.USD","LU0314104364.USD","MSB.AU","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","SG9999014013.SGD","LU2210149790.SGD","BK4588","IE00BN0W2T93.GBP","IE00BKPKM429.USD","BK7501","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631796605","title":"Mesoblast Reports Ryoncil® Net Revenues of US$30.3M and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631796605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631796605?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:55","pubTimestamp":1777510501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA9R8J7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","SG9999002224.SGD","LU0787776722.HKD","LU2264538146.SGD","LU1093756168.USD","BK7067","LU1093756325.SGD","SG9999002232.USD","IE000M9KFDE8.USD","BK7508","BK4206","BK4512","LU1988902786.USD","LU1064131342.USD","MMM","LU1894683264.USD","LU0683600562.USD","BK4534","BK4533","BK7501","MSB.AU","LU1894683348.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148152415","title":"Stock Track | Mesoblast Plummets 5.41% Intraday Following Quarterly Ryoncil Revenue Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1148152415","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148152415?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:30","pubTimestamp":1777509035,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock price dropped sharply by 5.41% during intraday trading on Thursday, as investors reacted to the company's latest quarterly financial update.The decline came shortly after...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631575532","title":"Mesoblast Ltd - Reports Qtrly Ryoncil Net Revenues of $30.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2631575532","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631575532?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:57","pubTimestamp":1777507051,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C20G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631520999","title":"ASX Growth Companies With High Insider Ownership In April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631520999","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631520999?lang=en_us&edition=fundamental","pubTime":"2026-04-30 03:08","pubTimestamp":1777489699,"startTime":"0","endTime":"0","summary":"As Australian shares enter their seventh consecutive day in the red, market sentiment has shifted into bearish territory amid concerns over rising inflation and potential interest rate hikes. In this challenging environment, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those who know the business best.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2054000-choice2-main-header/1585187245570","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2054000-choice2-main-header/1585187245570"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ipx/iperionx-shares/news/asx-growth-companies-with-high-insider-ownership-in-april-20-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ipx/iperionx-shares/news/asx-growth-companies-with-high-insider-ownership-in-april-20-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","XJO.AU","XKO.AU","SKS.AU","BK7116","BK7017","BK7104","BK7023","BK7016","BK7508","BK7110","AYA.AU","TOR.AU","MSB.AU","BK7067","MAU.AU","IPX.AU","BK7084","BK7501","FRS.AU","AR1.AU","BK7095","EIQ.AU","SPL.AU","XAO.AU","AV1.AU","BK7094","AEM.AU","ELS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631759459","title":"Mesoblast files Form 3 as director Lynette Cobley reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2631759459","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631759459?lang=en_us&edition=fundamental","pubTime":"2026-04-29 18:22","pubTimestamp":1777458121,"startTime":"0","endTime":"0","summary":"Mesoblast Form 3 shows director Lynette Elizabeth Cobley reporting 63,000 ordinary shares as of March 18, 2026.Filing also discloses 200,000 options exercisable at $1.72, expiring May 9, 2032.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL66nDbR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MSB.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156659915","title":"Stock Track | Mesoblast Soars 5.12% Intraday on Patient Recruitment Milestone in Phase 3 Back Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1156659915","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156659915?lang=en_us&edition=fundamental","pubTime":"2026-04-29 11:50","pubTimestamp":1777434632,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock surged 5.12% during intraday trading on Wednesday, following the company's announcement of a key development milestone for its chronic low back pain treatment.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631455426","title":"BUZZ-ASX-shares of Mesoblast rise after back-treatment drug hits patent target","url":"https://stock-news.laohu8.com/highlight/detail?id=2631455426","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631455426?lang=en_us&edition=fundamental","pubTime":"2026-04-29 11:22","pubTimestamp":1777432976,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-shares of Mesoblast rise after back-treatment drug hits patent target** Australian shares of Mesoblast MSB.AX rise as much as 4.2% to A$2.24, their biggest intraday pct gain since April 22** Stock among the top gainers in Australia's S&P/ASX 200 index .AXJO, which is down 0.3%** Stock set for a second consecutive session of gains, if current trend holds** The drugmaker says its lower back-treating drug, rexlemestrocel-L, has achieved patient recruitment target** The patent protects the drug from competition, supports higher longterm revenues** Despite moves, MSB down 17.8% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL6N41C048:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553071","title":"Mesoblast hits recruitment target in Phase 3 chronic low back pain trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553071","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631553071?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:53","pubTimestamp":1777424014,"startTime":"0","endTime":"0","summary":"Mesoblast hit recruitment target in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain tied to degenerative disc disease.Top-line results have not been presented yet; readout is expected in mid-CY2027.Study is designed to confirm earlier findings that rexlemestrocel-L reduced pain and supported lower opioid use.Positive results are intended to support an FDA filing in Q3 CY2027, with RMAT status positioning program for priority review once BLA is filed.Mesoblast framed indication as major commercial opportunity, citing potential peak-year revenue above USD 10 billion with single-digit market penetration.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6PvWb7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","NDAQ","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","BK7508","BK4112","LU2210149790.SGD","BK7501","BK4588","MSB.AU","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK7067","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553020","title":"Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631553020?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:53","pubTimestamp":1777423996,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUABQ0Y0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629750895","title":"Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2629750895","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629750895?lang=en_us&edition=fundamental","pubTime":"2026-04-24 10:19","pubTimestamp":1776997156,"startTime":"0","endTime":"0","summary":"Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7067","MSB","BK7508","MSB.AU","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628762489","title":"Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2628762489","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628762489?lang=en_us&edition=fundamental","pubTime":"2026-04-19 21:04","pubTimestamp":1776603864,"startTime":"0","endTime":"0","summary":"On 8 April 2026, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel‑L‑rknd) in 76 children with Duchenne muscular dystrophy, using time‑to‑stand at nine months as the primary endpoint.\nThis marks an expansion of Ryoncil’s use beyond steroid‑refractory acute graft‑versus‑host disease into another rare pediatric indication, leveraging its existing FDA‑approved manufacturing platform and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-61-after-fda-clears-registrational-dm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-61-after-fda-clears-registrational-dm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK4585","BK7508","BK4006","MSB.AU","BK7501","LABU","BK4588","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628109572","title":"Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2628109572","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628109572?lang=en_us&edition=fundamental","pubTime":"2026-04-16 22:08","pubTimestamp":1776348536,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) recently secured an exclusive worldwide license to a patented chimeric antigen receptor technology from Mayo Clinic, with the goal of refining the targeting and immune effects of its mesenchymal stromal cell therapies.\nSee our latest analysis for Mesoblast.\nAt a share price of A$2.24, Mesoblast has seen a 10.89% 1 month share price return and a 10.34% 7 day share price return. Over 90 days, the share price return is a 15.15% decline, while the 3 year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","BK4006","MSB","BK7501","BK7508","BK4230","BK7067","BK4022","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476087","title":"Mesoblast Acquires Exclusive License to Chimeric Antigen Receptor Platform; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476087","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476087?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:35","pubTimestamp":1776216917,"startTime":"0","endTime":"0","summary":"Mesoblast  acquired an exclusive license to a patented chimeric antigen receptor technology platform to boost the effectiveness of its products, according to a Wednesday filing with the Australian bourse.The company obtained the rights to the intellectual property developed at Mayo Clinic through the acquisition of a startup mainly formed to advance the technology, the filing said.Shares rose nearly 7% in morning trade Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","MSB.AU","BK4139","BK7508","BK7067","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476272","title":"Australian stocks edge higher as investors focus on US-Iran talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476272?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:30","pubTimestamp":1776216641,"startTime":"0","endTime":"0","summary":"Australian stocks edge higher as investors focus on US-Iran talks April 15 (Reuters) - Australian shares rose for a second straight session on Wednesday, with miners leading the rally, as signs that d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nL4N40Y012:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7507","BK7501","EVN.AU","BK7511","MSB.AU","BK7095","NST.AU","VGN.AU","BK7506","BK7067","BK7135","BK7104","BHP.AU","CBA.AU","BK7030","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":6,"totalSize":178,"code":"91000000","status":"200"}]}}